Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Air Products & Chemicals, Inc. (APD) vs Merck & Co., Inc. (MRK) Price & Performance

Air Products & Chemicals, Inc.Trade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Air Products & Chemicals, Inc. vs Merck & Co., Inc. — how do they compare? Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.63B), while Merck & Co., Inc. trades at $130.21 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 4.7× Air Products & Chemicals, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.

APDMRK
Market Cap
$68.63B$323.00B
Sector
Basic MaterialsHealth
52-Week High
$314.19$131.84
52-Week Low
$230.42$77.60
Enterprise Value
$85.80B$369.77B
Dividend Yield
2.35%2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Air Products & Chemicals, Inc.

Air Products and Chemicals (APD) trades at $303.44, up 1.17% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The stock shows strong analyst support with a consensus price target of $346, though high valuation ratios like a P/E of 30.86 and EV/EBITDA of 50.36 raise concerns. Recent news highlights a major semiconductor supply deal in Taiwan and raised guidance after Q3 2026 results.

The outlook is mixed: positive momentum from contract wins and earnings performance offers upside, but negative net income margins and elevated debt levels pose risks. Investors should weigh growth catalysts against financial leverage and profitability challenges.

Merck & Co., Inc.

MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.

Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Air Products & Chemicals, Inc.

Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.

Read more on APD

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK